- Home
- IRON vs EVT Comparison
IRON vs EVT Comparison
Compare IRON & EVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- EVT
- Stock Information
- Founded
- IRON 2017
- EVT 2003
- Country
- IRON United States
- EVT United States
- Employees
- IRON N/A
- EVT N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- EVT Finance Companies
- Sector
- IRON Health Care
- EVT Finance
- Exchange
- IRON Nasdaq
- EVT Nasdaq
- Market Cap
- IRON 2.1B
- EVT 1.9B
- IPO Year
- IRON N/A
- EVT N/A
- Fundamental
- Price
- IRON $67.78
- EVT $24.57
- Analyst Decision
- IRON Strong Buy
- EVT
- Analyst Count
- IRON 10
- EVT 0
- Target Price
- IRON $97.80
- EVT N/A
- AVG Volume (30 Days)
- IRON 380.9K
- EVT 115.5K
- Earning Date
- IRON 11-11-2025
- EVT 01-01-0001
- Dividend Yield
- IRON N/A
- EVT 8.32%
- EPS Growth
- IRON N/A
- EVT N/A
- EPS
- IRON N/A
- EVT 6.63
- Revenue
- IRON N/A
- EVT $69,404,302.00
- Revenue This Year
- IRON N/A
- EVT N/A
- Revenue Next Year
- IRON N/A
- EVT N/A
- P/E Ratio
- IRON N/A
- EVT $3.55
- Revenue Growth
- IRON N/A
- EVT N/A
- 52 Week Low
- IRON $30.82
- EVT $19.20
- 52 Week High
- IRON $68.79
- EVT $25.83
- Technical
- Relative Strength Index (RSI)
- IRON 69.97
- EVT 61.27
- Support Level
- IRON $65.26
- EVT $24.20
- Resistance Level
- IRON $68.79
- EVT $24.52
- Average True Range (ATR)
- IRON 2.67
- EVT 0.25
- MACD
- IRON 0.53
- EVT 0.03
- Stochastic Oscillator
- IRON 88.97
- EVT 86.09
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest
EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.